|
Orthologous residues
|
|
PIAS1 (human): S522‑p, PIAS1 (mouse): S522‑p, PIAS1 (rat): S522‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
bEnd3, HUVEC (endothelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
MAPKAPK2 (human)
|
siRNA inhibition of enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TNF
|
|
|
|
increase
|
|
|
siRNA
|
TNF
|
|
|
inhibit treatment-induced increase
|
MK2 siRNA
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced, sumoylation
|
|
Effect of modification (process):
transcription, inhibited
|
|
Comments:
PIAS1 S522A expression inhibits TNF-induced sumoylation of p53; inhibits inflammatory genes expression;
|
